|
From the GSK 2005 Annual Report:
"GSK expects to file Tykerb, an innovative once-daily oral treatment for breast cancer, in late 2006/H1 2007. GSK continues to investigate the use of Tykerb to treat other cancers. Data received in the quarter showed a survival benefit in renal cancer patients who over-express EGFR. Current treatment options for renal cancer are limited and these data, along with clinical studies on inflammatory breast cancer and brain metastases, have been submitted for presentation to ASCO in June 2006."
Tykerb is another name for Lapatinib.
Regards
Joe
|